lncb74
·Code: LNCB74
lncb74: sourced relationships with 1 company · 1 clinical trial tracked.
lncb74 evidence translation
What we can confirm
1 tracked trial
What it means
Source-backed records connect lncb74 to NXTC; that link alone does not prove the drug works.
What to watch
Watch trial status, endpoints, and the next source-backed update.
BioSniper AIPage evidence connected
Prepared research question
How could lncb74 → NXTC affect its developer, and what evidence supports the link?
Run cited research
Traceable citations · Unknowns marked
See linked entities and source evidence5 indications · 0 study sponsors
Related indications
Study sponsors
No additional listed-company sponsor is linked.
Dated Pipeline Records (1)
| Company | Dated record stage |
|---|---|
| NextCure, Inc. (NXTC) | Phase 1 |
Clinical Trial Registry Records (1)
A Phase 1, Open-label, Dose Escalation and Dose Expansion Study for LNCB74, a B7-H4 Targeted Antibody Drug Conjugate, as Monotherapy in Participants With Advanced Solid Tumors
Primary endpoint: Evaluate the safety and tolerability of LNCB74
InterventionalRandomizedopen145 targetStarted 2025-01Completion 2026-1214 sites · United StatesNextCure, Inc.
Frequently asked questions
Which companies have sourced relationships with lncb74?
lncb74 has dated SEC/FDA relationship records for NextCure, Inc..
How many clinical trials involve lncb74?
BioSniper tracks 1 clinical trial involving lncb74.